BioResponse® - a business unit of 20/20 GeneSystems Inc.

20/20 GeneSystems Inc. develops and commercializes diagnostic tests for the early detection of cancer to improve outcomes of people at high risk for specific types of cancers. It offers blood tests for use in the United States to aid in the early detection of lung cancer using a combined panel of biomarkers. The company also provides PAULA’s Test, a blood test for the early detection of lung cancer, which is available in the United States through licensed medical professionals; and universal pan-cancer risk profile. In addition, it offers BioCheck, a biological detection test kit for the screening of unknown suspicious powders by emergency personnel and first responders; and Layered ImmunoHistoChemistry to predict the efficacy of molecularly targeted therapies in cancer. The company’s BioCheck is used by agencies in the United States, Canada,